EMA professionals have served in an advisory capacity on the following transactions:
 

• Represented Quanta BioDesign, a manufacturer of cross-linking and labeling chemistries for life science and biopharmaceutical applications, in sale to Vector Laboratories, with backing from Thompson Street Capital Partners.  Terms undisclosed.*
• Represented Medtor, Inc., a medical device company focused on wearable vital signs monitoring, in sale to BioIntelliSense, Inc.  Terms undisclosed. *
• Represented BrightBox Quantitation, a maker of technology for rapid quantitation of next generation sequencing libraries, in sale to Calibre Scientific, Inc. Terms undisclosed. *
• Represented Velesco Pharmaceutical Services, a pharmaceutical Contract Development and Manufacturing Organization, in sale to Pace Analytical Services, LLC. Terms undisclosed.*
• Represented Canopy Biosciences, LLC, a leader in high multiplex biomarker imaging for immunology, immuno-oncology and cell therapy, in sale to Bruker Corporation (BRKR).  Terms undisclosed. *
• Advised Aradigm Corporation on sale of rare lung disease pharmaceutical assets to Grifols SA. Terms undisclosed. 
• Represented zPredicta, Inc., a 3D cell culture technologies company, in partnership agreement with LabCorp. Terms undisclosed.*
• Represented Transplant Genomics Inc., a molecular diagnostic testing company for monitoring of organ transplant patients, on a sale of the company to Eurofins Scientific (EUFI.PA). Terms undisclosed.*
• Represented Transplant Genomics Inc., a developer of diagnostic tests for transplant medicine, in financing round from Shanghai-based Genext Medical Technology. Terms undisclosed.*
• Represented Armune Bioscience, Inc. a developer of diagnostic tests for cancer, on sale to Exact Sciences Corporation (EXAS). Terms undisclosed.
• Advised Solulink, LLC, a maker of proprietary life science conjugation technologies, on a sale of certain assets to Maravai Life Sciences. Terms undisclosed.
• Represented Wasatch Microfluidics, LLC, a manufacturer of instrumentation for antibody screening, in a $10 million Series D preferred equity capital raise from Telegraph Hill Partners. Terms undisclosed.*
• Represented Avansci Bio, LLC, a manufacturer of tissue dissection instrumentation used in oncology diagnostics, in sale to Roche Diagnostics. Terms undisclosed.
• Represented Affymetrix, Inc. in its sale of Anatrace, a manufacturer of detergents for membrane protein research, to StoneCalibre Partners. Terms undisclosed.
• Sale of Transpire, Inc., a maker of radiation treatment planning software, to Varian Medical Systems. Terms undisclosed.
• Sale of Sandhill Scientific, a manufacturer of gastrointestinal devices, to Medovations, Inc. Terms undisclosed.*
• Sale of Aribex Inc., a manufacturer of dental imaging systems, to Danaher Corporation to a top five global medical device maker. Terms undisclosed.*
• Consulted with One Lambda, Inc., a life science technologies company, in its sale to ThermoFisher Scientific, Inc. Terms undisclosed.
• Sale of Braun BioSystems, Inc. to Medtronic, Inc. Terms undisclosed.
• Sale of Premier Medical, Inc., a respiratory services company, to The Riverside Company. Terms undisclosed.*
• Advised Advanced Cell Diagnostics, Inc., a maker of diagnostic tests for personalized medicine, on transaction with Ventana Medical Systems/Roche Diagnostics. Terms undisclosed.
• Represented BioMicro Systems, Inc. in its sale of all intellectual property assets relating to NimbleGen microarrays to Roche Diagnostics. Terms undisclosed.
• Sale of MicroBiologics, Inc., a producer of biological standards for laboratory use, to Granite Equity Partners. Transaction valued at $14 million.
• Sale of Airlift Unlimited, Inc., a producer of respiratory therapy devices, to Meridian Medical, LLC. Terms undisclosed.*
• Sale of First Opinion Corporation, a healthcare diagnostics software company, to Healthways, Inc. (HWAY). Terms undisclosed.
• Represented One Lambda, Inc. in licensing agreement with Luminex Corporation. Terms undisclosed.
• Sale of Panomics, Inc., a manufacturer of reagents and DNA expression technologies for life science research applications, to Affymetrix, Inc. (AFFY). Terms undisclosed.
• Sale of Environmental Resource Associates, Inc., a manufacturer of environmental standards for laboratory equipment, to Waters Corporation (WAT). Terms undisclosed.
• Represented Genaissance Pharmaceuticals, Inc. (GNSC), in its acquisition of Lark Technologies, Inc., a gene sequencing service company. Transaction valued at $10 million.
• $12 million preferred equity financing for GenoSpectra, Inc., a life sciences reagent company.
• Represented a $50 million revenue life sciences instrumentation and reagent company through multiple transactions, 9 in-licensing and acquisition projects, and the divestiture of one business unit. Terms undisclosed.
• Acquisition of the life science instrumentation division of GSI Lumonics, Inc. Transaction valued at $120 million.
• Initial public offering of Packard BioScience Company, a manufacturer of automated laboratory equipment and reagents for life science research applications. Transaction valued at $150 million.
• Merger of Packard BioScience Company with PerkinElmer, Inc. (PKI). Transaction valued at over $700 million.
• Sale of Canberra Industries, Inc., a manufacturer of nuclear detection instrumentation, to COGEMA, Inc. Transaction valued at $180 million.
• Represented buyer in acquisition of a $4 million revenue life sciences tool company with a unique labeling technology for life science research applications. Terms undisclosed.
• Sale of Immunex Corporation, a leader in immune system science innovation and manufacturer of leading rheumatoid arthritis drug, ENBREL, to Amgen Corporation (AMGN). Transaction valued at $16 billion.
• Acquisition of Tularik, a pioneer in drug discovery related to cell signaling and the control of gene expression, by Amgen Corporation (AMGN). Transaction valued at $1.3 billion.
• Negotiation of joint venture technology development agreements with multi- billion dollar medical device manufacturer. Terms undisclosed.
• Acquisition of multiple, independent nuclear detection instrumentation businesses in the U.S. and Europe. Transaction valued at over $20 million.
• Acquisition of Canadian life science tools distribution company. Transaction valued at $10 million.
• Acquisition of fiber-optic imaging business in the U.K. Terms undisclosed.
• Negotiation of license, joint development and distribution agreements with Sigma-Aldrich Corporation (SIAL) on behalf of early-stage biomarker and reagent company. Terms undisclosed.
• Negotiation of joint venture and licensing agreement with microfluidics company. Terms undisclosed.
• Negotiation of license agreement with Luminex, Inc. (LMNX). Terms undisclosed.
• Negotiation of license agreement for biomarker technology with Scripps Institute. Terms undisclosed.
• Negotiation of license and distribution agreement for gene expression technology with Bayer Healthcare, LLC, Diagnostics Division. Terms undisclosed.
• Negotiation of license agreement for fluorescent marker technology with Albert Einstein College of Medicine. Terms undisclosed.
• Negotiation of technology license agreements with The University of North Carolina at Chapel Hill, and the Centre National De Recherche Scientifique (CNRS). Terms undisclosed.
• Sale of Elekon Industries, Inc., a medical sensor company, to Measurement Specialties, Inc. (MSS). Terms undisclosed.
• Sale of Aerosport Corporation, a manufacturer of metabolic analysis equipment for clinical and sports applications, to Angeion Corporation (ANGN). Terms undisclosed.
• Sale of TERM Billing, Inc., a medical billing company, to Intermedix, Inc. with equity backing from Parthenon Capital. Terms undisclosed.
• Recapitalization of Emergency Care & Health Organization, Ltd., a physician practice company. Terms undisclosed.

*Principals of EMA acted in their capacity of registered securities agents of M&A Securities Group, Inc., Member Finra/SiPC on these transactions.

Back to Sectors